Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by mercedesmanon Jun 15, 2022 4:20pm
183 Views
Post# 34759368

Stock Dividend or Dialco Spinout ?

Stock Dividend or Dialco Spinout ?If (when?) there is a sale of the Dialco assets, you have to wonder if there will be a sale to mysterious 3rd party before Dialco is spun out to a separte trading entity (ie before the sale, a dividend of shares in Dialco to all Spectral shareholders) or whether there would be a straight sale of assets, out of the one entity (Spectral).  In the latter case, coffers would be filled with cash and then need to be divvied out to shareholders...assuming, of course, that they don't give it away.

Fresenius paid $ 2B USD for NxStage.  Before all their recent problems, Outset was valued at almost $ 2B USD as well.

Makes you wonder what a "game-changer" might be worth, in this new paradigm of HHD.

MM
<< Previous
Bullboard Posts
Next >>